Hints and tips:
...Banco Santander, BT Group, Centrica, CMC Markets, Co-operative Bank, CVS Group, Diageo, Enel, Hammerson, JCDecaux, L’Oréal, Leonardo, Nestlé, OMV, Orange, Relx, Rentokil Initial, Repsol, Royal Dutch Shell, Sanofi-Aventis...
...H1, Mastercard Q2, Merck & Co Q2, Nestlé H1, Nissan Motor Q1, Northrop Grumman Q2, OMV Q2, Orange H1, Panasonic Q1, Pfizer Q2, Relx H1, Rentokil Initial H1, Repsol Q2, Royal Dutch Shell Q2, Samsung Q2, Sanofi-Aventis...
...Q2 Mediobanca Q2 Merck & Co Q2 National Express H1 Nestle H1 Northrop Grumman Q2 Orange H1 Panasonic Q1 Pinterest Q1 Rentokil H1 Repsol Q2 Royal Dutch Shell Q2 Saint-Gobain H1 Samsung Q2 Sanofi-Aventis...
...It has been a year that most US distressed hedge funds would love to forget....
...Verily products like Onduo, a joint venture with Sanofi to create a diabetes management platform, might move closer to Google Health....
...Large corporations, including Unilever, Akzo Nobel and Sanofi, are all looking to dispose of multibillion units in the coming months and are all likely targets for private equity....
...Freemium v paid: Streaming competition swells YouTube is one of several Spotify competitors bringing streaming services to the market this year....
...As with Bush v Gore and Citizens United, the healthcare ruling could have a substantial impact on the direction of a US election....
...He also has served on the board of Genzyme, the biotech company sold to Sanofi-Aventis this year for more than $20bn....
...In a research note on Monday, Cowen argued that a number of the large pharmaceutical groups, led by Eli Lilly, Sanofi-Aventis and Pfizer, would be worth more if they divested separable business units, which...
...Sanofi-Aventis has continued aggressively to acquire others, including ultimately winning support for the takeover of US group Genzyme after raising its bid above $20bn....
...Diabetes medications still make up about 17 per cent of Lilly’s $22bn revenues, but in recent years it has lost ground to rivals such as Merck and Sanofi-Aventis....
...Sanofi-Aventis stepped up its pursuit of Genzyme on Sunday, outlining publicly its interest in a takeover deal as it inched closer to making a hostile offer for the US biotech company....
...High factory automation has helped contain V-Zug’s costs, including a smart new computerised logistics centre opened this year. “Productivity is a key success factor for us,” Mr Buhofer says....
...for NESV to become the new owners, but warns that if the club slips into administration it will be automatically docked nine points.Related link: Penalty fear over Liverpool fight October 12 2010 RBS v...
...Dehecq’s belated adieu Farewell Jean-François Dehecq, the man who built Sanofi-Aventis into a French-based pharmaceutical giant with global reach through bold acquisitions during the past four decades....
...“GSK’s 6 per cent 2011 dividend yield is as high as Sanofi-Aventis’, but comes without the risk of imminent big M&A and imminent major generics.”...
...In pharmaceuticals, the government engineered the merger between Sanofi and Aventis to create a new champion rather than allow the Swiss Novartis to swallow it up....
...“Our competitors get into these brand wars like Coke v Pepsi,” says Zimmer at UTA....
...The partnership was welcomed by markets and Sanofi-Aventis rose 1.4 per cent to €45.01....
...A study by a British medical journal reported that a blood-thinning pill developed by the company worked better than Plavix, a rival drug made by Sanofi-Aventis....
...“Regulators are generally a bit conservative and want to develop more experience,” says Li Zheng from Sanofi-Aventis....
...France’s Sanofi-Aventis climbed 7.5 per cent to €43.77, following the wider sector’s gains and enjoying a recommendation upgrade by JPMorgan, from “neutral” to “overweight”....
...The World Health Organisation on Monday said that leading vaccine producers including Novartis, GlaxoSmithKline and Sanofi-Aventis had requested “wild type virus” samples of the A (H1N1) virus....
...Elsewhere in the sector, Sanofi-Aventis advanced 3.4 per cent to €45.35, Novo Nordisk rose 1.8 per cent to DKr281.50 and Merck lost 0.3 per cent to €63....
International Edition